Amicus Therapeutics, Inc. (NASDAQ:FOLD)

CAPS Rating: 2 out of 5

A clinical-stage biopharmaceutical company, which focused on the discovery, development and commercialization of novel small molecule, orally-administered drugs, known as pharmacological chaperones, for the treatment of a range of human genetic diseases.

Recs

1
Player Avatar pchop123 (80.37) Submitted: 2/23/2013 12:37:27 PM : Outperform Start Price: $2.78 FOLD Score: -4.14

I like their cash position now, but they have to start getting some positive results over the next qtr in the clinical trials area

Featured Broker Partners


Advertisement